This is Thomas Sullivan - Policy & Medicine Writing Staff's Typepad Profile.
Join Typepad and start following Thomas Sullivan - Policy & Medicine Writing Staff's activity
Join Now!
Already a member? Sign In
Thomas Sullivan - Policy & Medicine Writing Staff
Columbia, Maryland
Former political consultant who founded Rockpointe, Inc. a bio-medical education company in 1995.
Interests: marketing, politics, baseball, cycling, medicine, university of florida sports, medical education, track and cross country, driving kids to various practices
Recent Activity
Image
As we previously reported, the CHRONIC Care Act of 2017 was introduced by Senate Finance Committee Chairman Orrin Hatch and Ranking Member Ron Wyden, along with Johnny Isakson and Mark Warner, the co-chairs of the Committee’s Chronic Care Working Group.... Continue reading
Posted 4 hours ago at Policy and Medicine
Image
On December 7, 2016, the HHS Office of the Inspector General ("OIG") approved new safe harbors to the federal anti-kickback statute (“AKS”) and amendments to the civil monetary penalty ("CMP") rules, including recognizing new statutory exceptions, seeking to alleviate blanket... Continue reading
Posted 4 hours ago at Policy and Medicine
Image
In February, the Federal Trade Commission filed a complaint in federal district court charging Shire ViroPharma Inc. with violating the antitrust laws by abusing government processes to delay generic competition to its branded prescription drug, Vancocin HCl Capsules. The complaint... Continue reading
Posted yesterday at Policy and Medicine
Image
You’d think, from listening to politicians and news anchors, that the cost of prescription drugs is the highest it has ever been, and continuing to rise out of control. However, in reality, growth in drug prices this year was half... Continue reading
Posted 2 days ago at Policy and Medicine
Image
Life sciences compliance departments are under constant pressure to roll out updated and comprehensive training that addresses a growing milieu of subject matter, from off-label promotion, HIPAA, and data security, to antibribery laws around the globe. The rush to cover... Continue reading
Posted 2 days ago at Policy and Medicine
Image
In 2012, FDA instituted a risk evaluation and mitigation strategy (REMS) for extended-release and long-acting (ER/LA) opioids that required companies marketing ER/LA opioids to provide a medication guide and make training available to prescribers. Under the REMS, the training must... Continue reading
Posted 3 days ago at Policy and Medicine
Image
Late last week, California passed legislation in the state senate that restricts pharmaceutical companies from giving gifts and incentives to medical professionals. The legislation restricts pharmaceutical companies from providing flights, travel, speaking fees, entertainment, consulting payments, or other financial benefits... Continue reading
Posted 4 days ago at Policy and Medicine
Image
The purpose of this article is to give manufacturers some initial background on the topics and some tools that could be considered.The review methodology described has been proven to help manufacturers and has been the starting point for developing an... Continue reading
Posted 4 days ago at Policy and Medicine
Image
As has been noted, CMS named 769 hospitals that will face Medicare payment cuts in fiscal year (FY) 2017 under the Hospital-Acquired Condition Reduction Program (HACRP), which for the first time considered rates of infection from antibiotic-resistant bacteria in its... Continue reading
Posted 7 days ago at Policy and Medicine
Image
Although the new code of conduct for member medical device and in-vitro diagnostic companies operating in the European marketplace has come into force the first day of this year, a grace period has been granted before new principles become effective.... Continue reading
Posted 7 days ago at Policy and Medicine
Image
On April 28, 2017, the United States Department of Justice announced a settlement with Quest Diagnostics, Inc., for $6 million to resolve a lawsuit by the United States alleging that Berkeley HeartLab Inc., of Alameda, California, violated the False Claims... Continue reading
Posted May 18, 2017 at Policy and Medicine
Image
On April 24, 2017, Sanofi-Aventis sued Mylan Inc. in a United States District Court in New Jersey over its effort to keep a rival to the EpiPen from gaining traction in the market. The filing claims that when Mylan learned... Continue reading
Posted May 17, 2017 at Policy and Medicine
Image
Over the last several years, the pharmaceutical industry has seen a steady increase in state legislation targeting the cost of prescription drugs. Although the cost of prescription drugs account for a small fraction of healthcare costs within the United States,... Continue reading
Posted May 17, 2017 at Policy and Medicine
Image
We have long been known to deride the national Open Payments database, believing that it does more harm than good. Recently, it was brought to our attention that the State of Florida has their own transparency database. FloridaHealthFinder.gov is a... Continue reading
Posted May 16, 2017 at Policy and Medicine
Image
Over the last two years, bipartisan Congressional interest in addressing prescription drug prices has been piqued. The interest is likely a result of a series of high profile and controversial decisions made by pharmaceutical companies such as Valeant, Turing, and... Continue reading
Posted May 15, 2017 at Policy and Medicine
Image
During the Medicare Payment Advisory Commission (MedPAC) April meeting, Commissioners discussed the medical device market. Since the medical device market is not a primary focus of the Commission, MedPAC staff made sure to introduce statistics on the industry at the... Continue reading
Posted May 12, 2017 at Policy and Medicine
Image
In early April, during the first session of the Medicare Payment Advisory Commission’s (MedPAC’s) public meeting, the Commission discussed Medicare Part B drug payment policy issues. During the meeting, the Commission unanimously approved several draft recommendations that are expected to... Continue reading
Posted May 11, 2017 at Policy and Medicine
Image
The American Board of Internal Medicine (ABIM) and the Accreditation Council for Continuing Medical Education (ACCME) have expanded their collaboration to recognize more accredited continuing medical education (CME) for Maintenance of Certification (MOC). With this expansion, accredited providers are now... Continue reading
Posted May 10, 2017 at Policy and Medicine
Image
One thing the pharmaceutical stock industry has seen over many decades is price sensitivity to small statements and comments made by those in the public eye. Recently, Jim Greenwood, President and CEO of the Biotechnology Innovation Organization (BIO), authored an... Continue reading
Posted May 9, 2017 at Policy and Medicine
Image
On Thursday, May 5, 2017, House Republicans finally got what they have been asking for, and campaigning on, for several years. They held a successful floor vote on the American Health Care Act (AHCA), approving the bill by a narrow... Continue reading
Posted May 8, 2017 at Policy and Medicine
Image
Novo Nordisk is in the midst of settling a whistleblower lawsuit that alleges that the company ran a “white-coat marketing scheme” to pump up sales of NovoLog, Victoza, and Levemir. The complaint was recently unsealed as part of the settlement... Continue reading
Posted May 5, 2017 at Policy and Medicine
Image
On Monday, May 1, 2017, the United States Court of Appeals for the Third Circuit stopped a False Claims Act suit that accused Genentech Inc. of defrauding Medicare by concealing certain side effects of its cancer drug Avastin, stating that... Continue reading
Posted May 4, 2017 at Policy and Medicine
Image
Many of our readers may remember back in October 2016, when Mylan agreed to pay $465 million to settle claims related to the way EpiPen was classified under the Medicaid rebate program. The settlement was based on allegations that the... Continue reading
Posted May 3, 2017 at Policy and Medicine
Image
New analysis from Amundsen Consulting, a division of QuintilesIMS, shows that more than half of commercially insured patients’ out-of-pocket spending for brand medicines is based on full list prices. Even though rebates paid by biopharmaceutical companies can substantially reduce the... Continue reading
Posted May 2, 2017 at Policy and Medicine
Image
In a paper titled Drug Shortages, Pricing, and Regulatory Activity, Christopher Stromberg of Bates White Economic Consulting examined “the patterns and causes of shortages in generic non-injectable drugs (e.g., tablets and topicals) in the United States.” The paper explores factors... Continue reading
Posted May 1, 2017 at Policy and Medicine